Molecular biomarkers of glial activation and injury in epilepsy

Stergios Boussios

doi:10.1016/j.drudis.2025.104289

Molecular biomarkers of glial activation and injury in epilepsy

Stergios Boussios

Research output: Contribution to journal › Article

13 Citations (Scopus)

Abstract

Increasing evidence from fluid biopsies suggests activation and injury of glial cells in epilepsy. The prevalence of clinical and subclinical seizures in neurodegenerative conditions such as Alzheimer's disease, frontotemporal dementia, and others merits review and comparison of the effects of seizures on glial markers in epilepsy and neurodegenerative diseases with concomitant seizures. Herein, we revisit preclinical and clinical reports of alterations in glial proteins in cerebrospinal fluid and blood associated with various types of epilepsy. We consider shared and distinct characteristics of changes in different age groups and sexes, in humans and animal models of epilepsy, and compare them with those reported in biofluids in neurodegenerative diseases. Our analysis indicates a significant overlap of glial response in these prevalent neurological conditions. [Abstract copyright: Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.]

Original language	English
Pages (from-to)	104289
Journal	Drug Discovery Today
Volume	30
Issue number	2
DOIs	https://doi.org/10.1016/j.drudis.2025.104289
Publication status	Published - 10 Jan 2025

Keywords

Fluid biopsy
GFAP
HMGB1
IL-1β
IL-6
Neurodegeneration
Neuroinflammation
S100β
Status epilepticus
TNF-α

Access to Document

10.1016/j.drudis.2025.104289Licence: CC BY

1-s2.0-S1359644625000029-main.pdfFinal published version, 915 KBLicence: CC BY

Cite this

@article{e4bd7e8500f440f9b1c8ef4c1c94b291,

title = "Molecular biomarkers of glial activation and injury in epilepsy",

abstract = "Increasing evidence from fluid biopsies suggests activation and injury of glial cells in epilepsy. The prevalence of clinical and subclinical seizures in neurodegenerative conditions such as Alzheimer's disease, frontotemporal dementia, and others merits review and comparison of the effects of seizures on glial markers in epilepsy and neurodegenerative diseases with concomitant seizures. Herein, we revisit preclinical and clinical reports of alterations in glial proteins in cerebrospinal fluid and blood associated with various types of epilepsy. We consider shared and distinct characteristics of changes in different age groups and sexes, in humans and animal models of epilepsy, and compare them with those reported in biofluids in neurodegenerative diseases. Our analysis indicates a significant overlap of glial response in these prevalent neurological conditions. [Abstract copyright: Copyright {\textcopyright} 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.]",

keywords = "Fluid biopsy, GFAP, HMGB1, IL-1β, IL-6, Neurodegeneration, Neuroinflammation, S100β, Status epilepticus, TNF-α",

author = "Stergios Boussios",

year = "2025",

month = jan,

day = "10",

doi = "10.1016/j.drudis.2025.104289",

language = "English",

volume = "30",

pages = "104289",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "2",

}

TY - JOUR

T1 - Molecular biomarkers of glial activation and injury in epilepsy

AU - Boussios, Stergios

PY - 2025/1/10

Y1 - 2025/1/10

N2 - Increasing evidence from fluid biopsies suggests activation and injury of glial cells in epilepsy. The prevalence of clinical and subclinical seizures in neurodegenerative conditions such as Alzheimer's disease, frontotemporal dementia, and others merits review and comparison of the effects of seizures on glial markers in epilepsy and neurodegenerative diseases with concomitant seizures. Herein, we revisit preclinical and clinical reports of alterations in glial proteins in cerebrospinal fluid and blood associated with various types of epilepsy. We consider shared and distinct characteristics of changes in different age groups and sexes, in humans and animal models of epilepsy, and compare them with those reported in biofluids in neurodegenerative diseases. Our analysis indicates a significant overlap of glial response in these prevalent neurological conditions. [Abstract copyright: Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.]

AB - Increasing evidence from fluid biopsies suggests activation and injury of glial cells in epilepsy. The prevalence of clinical and subclinical seizures in neurodegenerative conditions such as Alzheimer's disease, frontotemporal dementia, and others merits review and comparison of the effects of seizures on glial markers in epilepsy and neurodegenerative diseases with concomitant seizures. Herein, we revisit preclinical and clinical reports of alterations in glial proteins in cerebrospinal fluid and blood associated with various types of epilepsy. We consider shared and distinct characteristics of changes in different age groups and sexes, in humans and animal models of epilepsy, and compare them with those reported in biofluids in neurodegenerative diseases. Our analysis indicates a significant overlap of glial response in these prevalent neurological conditions. [Abstract copyright: Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.]

KW - Fluid biopsy

KW - GFAP

KW - HMGB1

KW - IL-1β

KW - IL-6

KW - Neurodegeneration

KW - Neuroinflammation

KW - S100β

KW - Status epilepticus

KW - TNF-α

U2 - 10.1016/j.drudis.2025.104289

DO - 10.1016/j.drudis.2025.104289

M3 - Article

SN - 1359-6446

VL - 30

SP - 104289

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 2

ER -

Molecular biomarkers of glial activation and injury in epilepsy

Abstract

Keywords

Access to Document

Fingerprint

Cite this